Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)
Completed · Phase 2 · NCT04442269
Conditions: Allergic Bronchopulmonary Aspergillosis
At a glance
- Research payments reported, 2025
- $2,185
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 62
About the trial
- Sponsor
- Regeneron Pharmaceuticals (with Sanofi)
- Tested
- dupilumab (drug), Placebo (drug)
- Dates
- Started 2020-09-15; completion 2024-02-09
- Results posted
- Yes
The primary objective of the study is to evaluate the efficacy of dupilumab on lung function in participants with Allergic Bronchopulmonary Aspergillosis (ABPA). The secondary objectives of the study are: * To evaluate the effects of dupilumab on exacerbations in participants with ABPA * To evaluate the effects of dupilumab on ABPA-related exacerbations * To evaluate the effects of dupilumab on hospitalization/emergency department (ED)/urgent care visits in participants with ABPA * To evaluate the effects of dupilumab on asthma control in participants with ABPA * To evaluate the effects of dupilumab on health-related quality of life (HRQoL) in participants with ABPA * To evaluate the effe…
From ClinicalTrials.gov, last updated 2025-04-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $2,185 in research payments for this study in 2025 (7 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $2,185
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.